Title: Pretreatment of patients with ST-segment elevation myocardial infarction with heparin: a systematic review and meta-analysis

Short Title: Pretreatment with heparin in STEMI patients

Authors: Gonçalo Costa^{1,2 (a)}, MD, MSc; Bernardo Resende^{1 (a)}, MD; Bárbara Oliveiros^{2,3}PhD; Lino Gonçalves^{1,2,3}, MD, PhD; Rogério Teixeira^{1,2,3}, MD, PhD ¹ Servico de Cardiologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

² Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal

³Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal

(a) Both authors share co-authorship

E-mail addresses:

Goncalo Costa: gnfcosta.93@gmail.com Bernardo Resende: bernardoresende028@gmail.com Bárbara Oliveiros: boliveiros@fmed.uc.pt Lino Gonçalves: lgoncalv@ci.uc.pt Rogério Teixeira: rogeriopteixeira@gmail.com

Corresponding author:

Name: Goncalo Nuno Ferraz Costa Address: Servico de Cardiologia, Hospital Geral – Centro Hospitalar e Universitário de Coimbra, Quinta dos Vales, S. Martinho do Bispo, 3041-801 Coimbra, Portugal **Telephone number:** +351911997603

Funding

The authors have no conflicts of interest to declare.

Total word count: 2854 words

ABSTRACT

Background: Unfractionated heparin (UFH) is frequently administered before percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI). However, current guidelines do not provide clear recommendations for UFH pretreatment before arrival at the coronary catheterisation laboratory.

Methods: Between June and July 2023, we systematically searched PubMed, Embase and Cochrane databases for studies comparing UFH pretreatments in patients with STEMI. A random-effects meta-analysis and meta-regression analyses were performed.

Results: Fourteen studies were included, of which four were randomised clinical trials (RCTs). A total of 76446 patients were included: 31238 in the pretreatment group and 39208 in the control group. Our meta-analysis revealed a lower all-cause mortality for the pretreatment strategy when compared with the control group, albeit with high heterogeneity (pooled odds ratio (OR) = 0.61, 95% confidence interval (CI) [0.49 - 0.76], P < 0.01; $I^2 = 77\%$); lower in-hospital cardiogenic shock (pooled OR = 0.68, 95% CI [0.58, 0.78], P < 0.21; $I^2 = 27\%$) and a higher rate of spontaneous reperfusion events (pooled OR = 1.68, 95% CI [1.47, 1.91], P < 0.01; $I^2 = 79\%$). In terms of major bleeding, the UFH pretreatment strategy further revealed a decreased rate of events (pooled OR = 0.85, 95% CI [0.73, 0.99], P = 0.40; $I^2 = 4\%$).

Conclusions: Our study suggests that UFH pretreatment in patients with STEMI undergoing primary PCI was associated to reduced all-cause mortality, cardiogenic shock, enhancing reperfusion rates, whilst diminishing major bleeding events.

ABREVIATIONS

CENTRAL: Cochrane Controlled Register of Trials CI: confidence interval ORs: odds ratios PCI: percutaneous coronary intervention RCTs: randomized clinical trials SCAAR: Swedish Coronary Angiography and Angioplasty Registry STEMI: ST-segment elevation myocardial infarction TIMI: Thrombolysis in Myocardial Infarction UFH: Unfractionated heparin

INTRODUCTION

Acute ST-elevation myocardial infarction (STEMI) is a life-threatening condition that requires prompt reperfusion therapy to minimise myocardial damage and improve patient outcomes. Percutaneous coronary intervention (PCI) is widely recognised as the gold standard treatment for patient with STEMI as it helps restore coronary blood flow and salvage ischaemic myocardium (1). However, the optimal antithrombotic strategy for the pretreatment of patients with STEMI undergoing PCI remains a topic of debate.

One common approach is heparin administration prior to patient arrival at the coronary catheterisation laboratory. Heparin, specifically unfractionated heparin (UFH), has been previously used in clinical practice to improve spontaneous reperfusion rates and reduce the clot burden (2). Improved coronary blood flow prior to PCI, which positively impacts patient outcomes, has been previously demonstrated (3). UFH is a rapidly acting anticoagulant with a short half-life of approximately 1–2 hours after intravenous administration (4). Its pharmacokinetic profile, coupled with antidote availability, means that UFH is a potential early-administration candidate in patients with STEMI.

Despite the widespread use of UFH during PCI, robust evidence is scarce on the benefits of administering anticoagulation at earlier stages within a PCI context. To date, only four small randomised controlled trials (RCTs) (2,5–7) and several observational studies (8–17) with varying results on patient-relevant outcomes have investigated UFH pretreatment in patients with STEMI undergoing PCI. Additionally, the evidence on mortality outcomes remains inconclusive. Consequently, recent European guidelines on acute coronary syndromes have endorsed UFH during PCI but they do not provide clear recommendations for UFH pretreatment before arrival at the coronary catheterisation laboratory (1).

Therefore, we conducted a systematic review and meta-analysis to evaluate efficacy and safety outcomes associated with UFH pretreatment in patients with STEMI undergoing primary PCI.

METHODS

Protocol and Registration

This study was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (**Supplementary Table 1**). This systematic review and meta-analysis were registered with the PROSPERO database (CRD42023422529).

In total, we made two changes to the original registry. Firstly, we expanded the scope of secondary outcomes to encompass stroke and major adverse cardiovascular outcomes. Additionally, we excluded post-PCI Thrombolysis in Myocardial Infarction (TIMI) flow-grade and no-reflow phenomena due to insufficient data. Secondly, we substituted the control arm, replacing UFH administration at the catheterisation laboratory with either no UFH pretreatment or delayed administration. This alteration mitigated a potential major limitation in study selection.

Literature Searches

We systematically checked the Cochrane Controlled Register of Trials (CENTRAL), EMBASE and PubMed between June and July 2023. In all databases, we accessed both interventional and observational studies which compared heparin pretreatment with delayed heparin administration in patients with STEMI in multiple combinations. Our selection criteria had no language or date restrictions. We also analysed bibliographic references in eligible studies to capture additional articles via cross referencing. The meta-analysis search and selection strategy is shown (**Figure 1**).

Eligibility Criteria

We used the following criteria to define study eligibility: 1) studies comparing the use of UFH pretreatment, prior to arrival at the catheterisation laboratory, with either no UFH pretreatment or delayed administration and 2) studies describing UFH administration timing and doses. We excluded studies reporting the use of other anticoagulant types as pretreatments that did not encompass full-text article publications and without control groups.

Primary and Secondary Outcomes

Primary outcomes were all-cause mortality and major bleeding events. Secondary endpoints were in-hospital cardiogenic shock, spontaneous reperfusion (defined as pre-PCI TIMI flow 2–3), stroke, cardiovascular mortality, major adverse cardiovascular outcomes, minor bleeding events and all bleeding events.

Data Collection and Management

Two authors systematically reviewed titles and abstracts of retrieved publications to identify studies meeting inclusion criteria. Any disagreements on study eligibility were resolved by consensus and discussion. Data collected from selected studies were subject to a narrative synthesis approach covering the study population,

including key demographics and clinical characteristics, interventions, and outcomes. For studies with multiple sequential publications, measures were taken to avoid the duplication of results. When summary data were not readily available, calculations were performed using available study data.

Risk of Bias and Certainty Assessments

Two authors independently assessed the risk of bias in articles according to the Cochrane Collaboration's "Risk of bias" tool for RCTs and the Newcastle–Ottawa Scale for observational studies. Studies with a high risk of bias were excluded. Quality evaluations for studies are presented in the "risk of bias summary" table (**Table 1**) or in the Newcastle–Ottawa Scale summary table (**Table 2**). Regarding certainty of evidence we used Grading of Recommendations, Assessment, Development and Evaluations framework.

Statistical Analysis

We conducted our meta-analysis to pool data across studies using a random effects model. The mean effect was considered significant if its 95% confidence interval (CI) did not include zero. Outcomes were addressed by estimating odds ratios (ORs). Statistical heterogeneity was evaluated by the visual inspection of forest plots, the I² statistical index (< 25% low, 25%–40% moderate and > 40% high heterogeneity) and Egger's linear regression tests. The software package used for the meta-analysis was Review Manager (RevMan) version 5.4.1. Meta-regression was performed considering one independent variable each time to generate regression model assumptions, such as the absence of multicollinearity and at least 5–10 cases (case studies) per independent variable. Moreover, due to limited complete pairwise data, multiple meta-regression was not valid. We applied a random-effects model using DerSimonian–Laird and

Knapp–Hartung standard error adjustment methods using meta-regression procedures in IBM SPSS, version 28. All data were evaluated at a 5% significance level (P<0.05).

RESULTS

Search Results

Our literature search identified 628 relevant records. Following duplicate removal, 525 publications were excluded based on pre-defined inclusion and exclusion criteria. Finally, 14 studies, 4 RCTs (2,5–7) and 10 observational studies (8–17), were included (**Figure 1**) with a total of 76446 patients: 31238 in the pretreatment group and 39208 in the control group. Most studies used UFH doses between 5000-10000 U or 90 U/kg. Two studies opted for a high dose of 300 U/kg in the intervention arm. The timing of pretreatment varied, often given during transport to a PCI-capable hospital. While most studies mention aspirin loading, the choice of P2Y12 inhibitors varied, with clopidogrel being the most common. Study characteristics of selected studies are presented in **Table 3** and baseline patient characteristics are summarised in **Table 4**.

Primary Outcomes

Our meta-analysis identified lower all-cause mortality rates using a pretreatment strategy when compared with a control group, albeit with high heterogeneity (pooled OR = 0.61, 95% CI [0.49, 0.76], P < 0.01; $I^2 = 77\%$). In subgroup analyses, in-hospital and 30-day mortality maintained statistical significance (pooled OR = 0.60, 95% CI [0.42, 0.86], P < 0.41; $I^2 = 0\%$; pooled OR = 0.63, 95% CI [0.46, 0.86], P < 0.01; $I^2 = 81\%$, respectively). A reduction in mortality effects was also observed for 1-year all-cause mortality, but with high heterogeneity (pooled OR = 0.56, 95% CI [0.32, 0.96], P < 0.01; $I^2 = 91\%$) (**Figure 2, Figure S1**). In meta-regression analyses, age ratio (b = -0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), aspirin ratio (b = -0.81; p = 0.378), PY12 inhibitor ratio (b = -0.49; p = 0.90; p = 0.786), p = 0.786), p = 0.786), p = 0.786), p = 0.786

0.351), ticagrelor ratio (b = -0.06; p = 0.519) or 'time to PCI' (b = 0.18; p = 0.519) were not predictors of the evaluated effect size. However, the effect size tended to be greater when the clopidogrel ratio was smaller (b = -0.89; p = 0.026) (**Figure S2**).

In terms of major bleeding, the pretreatment strategy further revealed a decreased rate of events (pooled OR = 0.85, 95% CI [0.73, 0.99], P = 0.40; $I^2 = 4\%$) (Figure 3, Figure S3).

Secondary Outcomes

In terms of secondary outcomes, in-hospital cardiogenic shock was statistically significantly favourable for the pretreatment strategy (pooled OR = 0.68, 95% CI [0.58, 0.78], P < 0.21; $I^2 = 27\%$) (Figure 4, Figure S4). Additionally, the pretreatment strategy exhibited a significantly higher rate of spontaneous reperfusion events (pooled OR = 1.68, 95% CI [1.47, 1.91], P < 0.01; $I^2 = 79\%$) (Figure 5, Figure S5) and stroke (pooled OR = 0.94, 95% CI [0.66, 1.34], P = 0.98; $I^2 = 0\%$). Cardiovascular mortality, major adverse cardiovascular events, minor bleeding and all-bleeding analyses were not performed due to insufficient data reported in the included studies.

Risk of Bias and Evidence Certainty

Overall, selected studies demonstrated a low-moderate risk of bias. However, due to the nature of the intervention, a high risk of bias was observed in participant and personnel blinding (**Tables 3 and 4**). Therefore, considering our results and the risk of bias in terms of our robust evidence, we considered low certainty for primary outcomes and very low for secondary outcomes (**Supplementary Table 2**).

DISCUSSION

We performed a systematic review and meta-analysis on the efficacy and safety outcomes of UFH pretreatment in patients with STEMI undergoing primary PCI. We observed that UFH pretreatment was associated with a lower risk of all-cause mortality, in-hospital cardiogenic shock and spontaneous reperfusion events. Furthermore, an improvement in safety outcomes was observed for reduced major bleeding events between groups.

Current guidelines recommend adjunctive antithrombotic treatment with antiplatelet and anticoagulant medication before primary PCI in patients diagnosed with STEMI, but ideal administration times remain controversial (1).

The notable reduction in all-cause mortality associated with UFH pretreatment underscores its potential as a valuable intervention; enhanced coronary blood flow before primary PCI which mitigates myocardial damage is compelling. Previous studies have suggested that UFH, as a rapidly acting anticoagulant, may facilitate spontaneous reperfusion rates and reduce the clot burden (2). This mechanism is particularly relevant within the STEMI context, where rapid and effective reperfusion is a critical determinant of patient outcomes (3), as shown by favourable outcomes in in-hospital, 30-day and 1-year mortality in our analyses. These findings further support the potential use of UFH pretreatment during critical post-PCI phases and in reducing early mortality.

By aligning the potential benefits of efficacy effects with safety considerations, the assessment of major bleeding events revealed a significant difference in the pretreatment group when compared with the control group. This observation did not exclude safety clinical evaluations before UFH pretreatment, especially given the delicate balance between preventing thrombotic events and avoiding bleeding

complications (18). While acknowledging our results for this outcome, the caveat is that not enough data are available to support this conclusion when applied to elderly and frail patients.

Beyond mortality and haemorrhagic events, a substantial reduction in in-hospital cardiogenic shock associated with UFH pretreatment has profound clinical implications. Cardiogenic shock is a pivotal determinant of patient prognosis post-STEMI (19). Previous studies have demonstrated associations between successful reperfusion and a reduced risk of cardiogenic shock (20), so any intervention that potentially mitigates its occurrence warrants careful consideration. The observed reduction in this high-risk complication suggests that UFH pretreatment may help improve haemodynamic stability during acute STEMI phases, thus potentially impacting the broader course of the disease.

Moreover, our analyses identified a significant increase in spontaneous reperfusion event rates upon UFH pretreatment. Swift and effective reperfusion lies at the core of STEMI management (3), and this finding aligns with the mechanistic rationale underpinning UFH pretreatment. The potential for UFH to enhance the early restoration of coronary blood flow introduces an intriguing facet to the clinical benefits of the strategy. This prompts further exploration into the mechanisms underlying these outcomes, potentially involving thrombus burden reduction, and enhancing coronary flow.

In light of recent research, the study by Emilsson et al. (12), a well-conducted and -powered study, provides a valuable addition to the UFH pretreatment debate in patients with STEMI. By analysing data from the Swedish Coronary Angiography and Angioplasty Registry, Emilsson's research aligns with our findings. The identification of a significantly lower risk of 30-day mortality, major bleeding events and cardiogenic

shock lends further credence to the potential benefits of UFH pretreatment in improving patient outcomes.

Moreover, in two studies by Giralt et al (13,14), both having significant weight in our meta-analysis, the authors witnessed a sustained reduction in mortality outcomes, whether in-hospital, 30-day or 1-year mortality, and lower rates of in-hospital cardiogenic shock. However, both analyses showed similar grades of major bleeding events between groups despite a slight no-benefit-tendency in the pretreatment group. We observed that the mean door-to-balloon time in Emilson et al. was somewhat higher when compared with the studies by Giralt et al., which may explain these differences.

Collectively, our systematic review and meta-analysis provide crucial insights into the potential benefits and limitations of UFH pretreatment in primary PCI for patients with STEMI. The reduction in all-cause mortality, coupled with improvements in in-hospital cardiogenic shock and spontaneous reperfusion rates, underscores the potential advantages of this strategy. Although the absence of significant differences in major bleeding and stroke suggests potential safety issues, further exploration is warranted. Rigorous, large-scale RCTs with standardised protocols and reported outcomes are pivotal in establishing definitive efficacy and safety evidence for UFH pretreatment. This evidence will not only guide clinical decision-making but also optimise outcomes in the dynamic STEMI management field.

Study Limitations

By acknowledging study strengths and limitations, some aspects of our research require careful consideration. Inherent heterogeneity across selected studies, stemming from variations in patient characteristics, UFH dosages and different concomitant antiplatelet regimens, may have introduced potential biases and limited the generalisability of our findings. A major difficulty in our study was different UFH

administration timings in the pretreatment group, which limited the determination of exact administration times for anticoagulation and PCI treatments. Due to a lack of data in selected studies, we were unable to assess heparin drug-related problems such as heparin-induced thrombocytopenia or osteopenia (21,22). Due to the low incidence of these issues (23), we hypothesize that they exert a low impact on the choice of UFH as an anticoagulant therapy.

Despite these challenges, we addressed these concerns by analysing a significative number of studies using strong statistical methods and robust subgroup analyses. The absence of comprehensive reporting for specific outcomes, such as cardiovascular mortality, major adverse cardiovascular events, minor bleeding, and all bleeding events, underscores the importance of standardised reporting in future research.

CONCLUSION

From our study, UFH pretreatment in patients with STEMI undergoing primary PCI has potential promise in reducing mortality, cardiogenic shock and enhancing reperfusion rates. High-scale RCTs are required to address these clinical questions in the future.

Author Contributions

GC: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Writing – original draft; BR: Data curation, Formal analysis, Methodology, Writing – original draft; BO: Supervision, Formal analysis; LG: Supervision, Writing - review & editing; RT: conception and design, interpretation of

data, revision of the manuscript, final approval and is responsible for the overall content as guarantor.

REFERENCES

- Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023 Aug;ehad191.
- Karlsson S, Andell P, Mohammad MA, Koul S, Olivecrona GK, James SK, et al. Editor's Choice- Heparin pre-treatment in patients with ST-segment elevation myocardial infarction and the risk of intracoronary thrombus and total vessel occlusion. Insights from the TASTE trial. Eur Hear journal Acute Cardiovasc care [Internet]. 2019 Feb 1 [cited 2023 Jun 5];8(1):15–23. Available from: https://pubmed.ncbi.nlm.nih.gov/28862032/
- 3. Stone GW, Cox D, Garcia E, Brodie BR, Morice MC, Griffin J, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation [Internet]. 2001 Aug 7 [cited 2023 Jun 5];104(6):636–41. Available from: https://pubmed.ncbi.nlm.nih.gov/11489767/
- Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet [Internet]. 1992 [cited 2023 Jun 5];22(5):359–74. Available from: https://pubmed.ncbi.nlm.nih.gov/1505142/
- Braga JC, Esteves FP, Esteves JP, Latado AL, Godinho AG, Azevedo A, et al. Confirmation that heparin is an alternative means of promoting early reperfusion. Coron Artery Dis [Internet]. 1998 [cited 2023 Jun 5];9(6):335–8. Available from:

https://pubmed.ncbi.nlm.nih.gov/9812183/

- Cantor WJ, Lavi S, Džavík V, Cairns J, Cheema AN, Della Siega A, et al. Upstream anticoagulation for patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the TOTAL trial. Catheter Cardiovasc Interv. 2020;96(3):519–25.
- 7. Fakhr-Mousavi A, Cheshmkhorooshan S, Vakilpour A, Mousavi SM. The effect of heparin administration time on thrombolysis in myocardial infarction flow grade in patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention. ARYA Atheroscler [Internet]. 2022 May 1 [cited 2023 Jun 5];18(3):1–7. Available from: https://europepmc.org/articles/PMC9931947
- Ariza A, Ferreiro JL, Sánchez-Salado JC, Lorente V, Gómez-Hospital JA, Cequier Á. Early Anticoagulation May Improve Preprocedural Patency of the Infarct-related Artery in Primary Percutaneous Coronary Intervention. Rev Española Cardiol (English Ed. 2013;66(2):148–50.
- 9. Bloom JE, Andrew E, Nehme Z, Dinh DT, Fernando H, Shi WY, et al. Prehospital heparin use for ST-elevation myocardial infarction is safe and improves angiographic outcomes. Eur Hear Journal Acute Cardiovasc Care [Internet]. 2021 Dec 18 [cited 2023 Jun 5];10(10):1140–7. Available from: https://academic.oup.com/ehjacc/article/10/10/1140/6311429
- Chung WY, Han MJ, Cho YS, Kim K II, Chang HJ, Youn TJ, et al. Effects of the early administration of heparin in patients with ST-elevation myocardial infarction treated by primary angioplasty. Circ J [Internet]. 2007 [cited 2023 Jun 5];71(6):862–7. Available from: https://pubmed.ncbi.nlm.nih.gov/17526981/
- 11. d'Entremont MA, Laferrière C, Bérubé S, Couture ÉL, Lepage S, Huynh T, et al.

> The effect of ASA, ticagrelor, and heparin in ST-segment myocardial infarction patients with prolonged transport times to primary percutaneous intervention. Catheter Cardiovasc Interv [Internet]. 2021 Mar 1 [cited 2023 Jun 5];97(4):591– 9. Available from: https://pubmed.ncbi.nlm.nih.gov/32860646/

- Emilsson OL, Bergman S, Mohammad MA, Olivecrona GK, Götberg M, Erlinge D, et al. Pretreatment with heparin in patients with ST-segment elevation myocardial infarction: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). EuroIntervention. 2022 Oct 1;18(9):709–18.
- Giralt T, Carrillo X, Rodriguez-Leor O, Fernandez-Nofrerias E, Rueda F, Serra-Flores J, et al. Time-dependent effects of unfractionated heparin in patients with ST-elevation myocardial infarction transferred for primary angioplasty. Int J Cardiol [Internet]. 2015 Aug 28 [cited 2023 Jun 5];198:70–4. Available from: https://pubmed.ncbi.nlm.nih.gov/26159240/
- Giralt T, Ribas N, Freixa X, Sabaté M, Caldentey G, Tizón-Marcos H, et al. Impact of pre-angioplasty antithrombotic therapy administration on coronary reperfusion in ST-segment elevation myocardial infarction: Does time matter? Int J Cardiol. 2021;325:9–15.
- 15. Mcginley C, Mordi IR, Kell P, Currie P, Hutcheon S, Koch S, et al. Prehospital Administration of Unfractionated Heparin in ST-Segment Elevation Myocardial Infarction Is Associated With Improved Long-Term Survival. J Cardiovasc Pharmacol. 2020;76(2):159–63.
- 16. Verheugt FWA, Liem A, Zijlstra F, Marsh RC, Veen G, Bronzwaer JGF. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: Results of the heparin in early patency (HEAP) pilot study. J Am Coll Cardiol. 1998;31(2):289–93.

- 17. Żurowska-Wolak M, Owsiak M, Bartuś S, Mikos M. The influence of prehospital medication administration in ST-elevation myocardial infarction patients on left ventricular ejection fraction and intra-hospital death. Postep w Kardiol Interwencyjnej. 2021;17(1):39–45.
- Zidane M, Schram MT, Planken EW, Molendijk WH, Rosendaal FR, Van Der Meer FJM, et al. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: A study in routine clinical practice. Arch Intern Med. 2000;160(15):2369–73.
- Dalzell JR. Review of Cardiogenic Shock After Acute Myocardial Infarction. Jama. 2022;327(9):878.
- Zeymer U, Huber K, fu Y, Ross A, Granger C, Goldstein P, et al. Impact of TIMI
 3 patency before primary percutaneous coronary intervention for ST-elevation
 myocardial infarction on clinical outcome: Results from the ASSENT-4 PCI
 study. Eur Hear J Acute Cardiovasc Care. 2012;1(2):136–42.
- Bussey H, Francis JL. Heparin overview and issues. Pharmacotherapy. 2004;24(8
 II).
- Niccolai CS, Hicks RW, Oertel L, Francis JL. Unfractionated heparin: Focus on a high-alert drug. Pharmacotherapy. 2004;24(8 II).
- Hogan M, Berger JS. Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management. Vasc Med (United Kingdom).
 2020;25(2):160–73.

FIGURE LEGENDS

Figure 1. Literature search flow diagram.

Figure 2. Forest plot showing all-cause mortality comparing unfractionated heparin pretreatment versus delayed administration. *M*–H, Mantel–Haenszel.

Figure 3. Forest plot showing major bleeding events comparing unfractionated heparin pretreatment versus delayed administration. *M*–*H*, Mantel–Haenszel.

Figure 4. Forest plot showing in-hospital cardiogenic shock comparing unfractionated heparin pretreatment versus delayed administration. *M*–*H*, Mantel–Haenszel.

Figure 5. Forest plot showing spontaneous reperfusion events (pre-percutaneous coronary intervention Thrombolysis in Myocardial Infarction flow 2–3) comparing unfractionated heparin pretreatment versus delayed administration. M–H, Mantel–Haensz

Table Legends



Table 1. Risk of bias summary. Green circle – low risk of bias; Red circle – high circle of bias.

Study	Selection	Comparability	Outcome	Total
Ariza et al, 2013	****	-	*	5
Bloom et al, 2021	****	-	***	7
d'Entremont et al, 2020	***	**	*	6
Emilsson et al, 2022	****	**	***	9
Giralt et al, 2015	****	**	***	9
Giralt et al, 2020	****	-	***	7
McGinley et al, 2020	***	**	***	8
Verheugt et al, 1998	***	*	***	7
Żurowska-Wolak et al, 2021	****	-	***	7

Table 2. Newcastle-Ottawa Scale summary. * - 1 point

Study Design		n (%)		Timing of UFH administration		IV UFH d	ose scheme	Concomitant antipla	atelet drug: Dose, n (%)	Follow-up	
j		Pretreatment group	Control group	Pretreatment group	Control group	Pretreatment group	Control group	Pretreatment group	Control group		
Ariza et al, 2013	Prospective	566 (57.8)	414 (42.2)	Transport or ER	CL	0.75-1mg/Kg and extra dose cording to ACT	1 mg/Kg (8% of the patients received bivalirudin)	• Aspirin, NR: 566 (100.0) • Clopidogrel: 600mg, 538 (95.0)	 Aspirin: NR, 412 (99.5) Clopidogrel: 300 or 600mg, 401 (98.1) 	Evaluation pre and post PCI	
Bloom et al, 2021	Retrospective	1392(29.5)	3328(70.5)	Transport	ER or CL	4000U plus 1000U in 1 hour	NR	• Aspirin: NR, 1346 (96.7) • Ticagrelor: NR, 947 (68.0)	 Aspirin: NR 3148 (94.6) Ticagrelor: NR, 2140 (64.3) GpIIb/IIIa inhibitor: NR, 1281 (38.5) 	30 days	
Braga et al, 1998	Randomized clinical trial	25 (52.1)	23 (47.9)	ER	CL	300U/Kg	5000-10000U	• Aspirin: 200mg, 25 (100.0)	• Aspirin: 200mg, 23 (100.0)	Evaluation pre and post PCI	
Cantor et al, 2019	Randomized clinical trial subanalysis	5422 (65.2)	2,889 (34.8)	Transport or ER	CL	7,688.3 ± 3,686.9U	6,936.6 ± 3,358.9U	 Aspirin: NR, NR Clopidogrel: NR, NR Prasugrel: NR, NR Ticagrelor: NR, NR 	 Aspirin: NR, NR Clopidogrel: NR, NR Prasugrel: NR, NR Ticagrelor: NR, NR 	1 year	
Chung et al, 2007	Retrospective	56 (46.7)	64 (53.3)	Transport or ER	After PCI	60U/Kg plus 14U/Kg/h until PCI or 1mg/Kg SC enoxaparin	100U/Kg	• Aspirin: 300mg, 56 (100.0) • Clopidogrel: 300mg, 56 (100.0)	Aspirin: 300mg, 64 (100.0)Clopidogrel: 300mg, 64 (100.0)	8.6±5.0 days	
d'Entremont et al, 2020	Retrospective	482 (68.0)	227 (32.0)	Non-PCI capable center before transport	CL	60U/Kg	60U/Kg	Aspirin: 320mg, 482 (100.0)Ticagrelor: 180mg, 482 (100.0)	Aspirin: 320mg, 227 (100.0)Ticagrelor: 180mg, 227 (100.0)	NR	
Emilsson et al, 2022	Retrospective	16026 (38.5)	25605 (61.5)	NR	CL	NR	NR	 Aspirin: NR, 15332 (95.7) Clopidogrel: NR, 5581 (34.8) Ticagrelor: NR, 7688 (48.0) 	 Aspirin: NR, 25112 (98.1) Clopidogrel: NR, 14986 (58.5) Ticagrelor: NR, 10120 (39.6) 	30 days	
Fakhr-Mousavi et al, 2021	Randomized clinical trial	92 (54.4)	77 (45.6)	ER	CL	90U/Kg	90U/kg	 Aspirin: 325mg, 92 (100.0) Clopidogrel: 600mg, 92 (100.0) 	 Aspirin: 325mg, 77 (100.0) Clopidogrel: 600mg, 77 (100.0) 	40 days	
Giralt et al, 2015	Retrospective	758 (57.2)	568 (42.8)	Non-PCI capable center before transport or during transport	CL	5000U	5000U	• Aspirin: 300mg, 744 (98.2) • Clopidogrel: 600mg, 742 (97.9)	• Aspirin: 300mg, 531 (93.5) • Clopidogrel: 300mg, 503 (88.6)	1 year	
Giralt et al, 2020	Prospective	2720 (77.3)	800 (22.7)	>31 minutes before PCI	Administered <30 minutes before PCI	70-100 U/Kg (5000U maximum)	70-100 U/Kg (5000U maximum)	• Clopidogrel: 600mg, 1973 (72.5) • Ticagrelor or Prasugrel: 180 or 60mg, 654 (24.0)	 Aspirin: 250-300mg, 655 (81.9) Clopidogrel: 600mg, 492 (61.5) Ticagrelor or Prasugrel: 180 or 60mg, 117 (14.6) 	1 year	
Karlsson et al, 2019	Randomized clinical trial subanalysis	2898 (40.6)	4246 (59.4)	Non-PCI capable center before transport or during transport or in ER	CL	NR	NR	• Aspirin: NR, 2817 (97.2) • Clopidogrel: NR, 1662 (57.4) • Ticagrelor: NR, 731 (25.2)	 Aspirin: NR, 3636 (85.6) Clopidogrel: NR, 2489 (58.6) Ticagrelor: NR, 578 (13.6) 	30 days	
McGinley et al, 2020	Retrospective	437 (43.7)	563 (56.3)	In transport	CL	5000U	NR	Aspirin: 300mg, 437 (100.0)Clopidogrel: 300mg, 437 (100.0)	NR	5 years	
Verheugt et al, 1998	Quasi- experimental comparative study	108 (50.0)	108 (50.0)	ER	CL	300U/Kg	NR	• Aspirin: 160mg, 108 (100.0)	• Aspirin: 160mg, 108 (100.0)	Evaluation pre and post PCI	
Żurowska- Wolak et al, 2021	Retrospective	256 (46.4)	296 (53.6)	Transport	ER or CL	NR	NR	• Clopidogrel: NR, NR	• Clopidogrel: NR, NR	1 year	
Table 3.	Characteris	stics of sele	ected stud	ies. ACT =	Activated	Clotting Tim	e, $\overline{\mathbf{CL}} = \mathbf{Cathe}$	eterisation Laboratory,	ER = Emergency Room	m, GpIIb/IIIa =	

Glycoprotein IIb/IIIa, IV = Intravenous, NR = Not Reported, PCI = Percutaneous Coronary Intervention, SC = Subcutaneous, UF = Unfractionated Heparin.

	Α	ge	Males	sex	Hyperter	nsion	Diabetes r	nelittus	Current	moking	Door-to	-balloon	Killip clas	s, I/II/III/IV
Study	Mean±SD		n (%)		n (%)		n (%)		n (%)		time (min)		(%)	
Study	Pretreatment	Control	Pretreatment	Control	Pretreatment	Control	Pretreatment	Control	Pretreatment	Control	Pretreatment	Control	Pretreatment	Control group
	group	group	group	group	group	group	group	group	group	group	group	group	group	Control group
Ariza et al, 2013	61.6±12.4	62.2±13.8	450 (79.5)	324 (78.3)	301 (53.2)	234 (56.5)	133 (23.5)	102 (24.6)	272 (48.0)	196 (47.3)	73.2 ± 36.3	66.5 ± 37.1	NR	NR
Bloom et al, 2021	62.0±12.4	64.0±13.2	1116 (80.2)	2505 (75.3)	NR	NR	203 (14.6)	583 (17.5)	NR	NR	48 ± 23	64 ± 47	NR	NR

Table 4. Patient demographics and baseline characteristics. NR = Not Reported, SD = Standard deviation	

Braga et al, 1998	62.0±12.0	64.0±10.0	16 (64.0)	13 (57.0)	13 (52.0)	15 (65.0)	5 (20.0)	3 (13.0)	16 (64.0)	11 (48.0)	71.0 ± 52.0	68.0 ± 17.0	NR	NR
Cantor et al, 2019	61.1±11.8	60.9±12.0	4955 (77.7)	2843 (77.2)	3,194 (50.1)	1,854 (50.4)	1,208 (18.9)	647 (17.6)	2,908 (45.6)	1,690 (45.9)	86.6 ± 329.0	60.9 ± 108.2	NR	NR
Chung et al, 2007	61.0±13.0	$60.0{\pm}14.0$	48 (85.7)	52 (81.3)	25 (45.0)	37 (58.0)	16 (29.0)	14 (22.0)	28 (50.0)	25.0 (39.0)	125±65	124±53	68.0/14.0/2.0/16.0	66.0/3.0/4.0/15.0
d'Entremont et al, 2020	62.7±12.0	64.2±12.1	368 (76.3)	174 (76.7)	215 (44.7)	114 (50.2)	83 (17.3)	32 (14.1)	205 (42.6)	118 (52.0)	118 (98,146)	87 (70, 100)	NR	NR
Emilsson et al, 2022	67.0±12.0	67.0±12.0	11259 (70.0)	18,381 (71.8)	7,118 (44.4)	11,430 (44.6)	2,318 (14.5)	3,812 (14.9)	4,662 (29.1)	6,514 (25.4)	276±244	290±270	NR	NR
Fakhr-Mousavi et al, 2022	57.1±8.8	57.5±7.5	72.0 (78.3)	60 (77.9)	32 (34.8)	41 (53.2)	13 (14.1)	23 (29.9)	NR	NR	NR	NR	96.7/2.2/1.1/-	97.4/2.6/-/-
Giralt et al, 2015	61.3±12.8	63.4±12.8	618 (81.5)	434 (76.4)	407 (53.7)	291 (51.2)	163 (21.5)	140 (24.6)	344 (45.4)	237 (41.7)	107 (86,133)	105 (83,140)	85.0/9.1/2.0/4.0	74.1/13.4/4.9/7.6
Giralt et al, 2020	65.4±14.0	 994 patients: 62.6±12.8 1091 patients: 62.3±12.8 635 patients: 64.4±13.4 	2173 (79.9)	600 (75.0)	1417 (52.1)	461 (57.6)	464 (17.1)	150 (18.8)	1190 (43.8)	281 (35.1)	 994 patients: 82.0 (68.0;103) 1091 patients: 101 (88.0;122) 635 patients: 140 (121;175) 	109 (78.0,161)	82.5/8.0/2.2/5.9	79.8/7.4/2.8/10.0
Karlsson et al, 2019	66.0±11.5	66.0±11.6	2169 (74.8)	3177 (74.8)	1172 (40.8)	1850 (44.3)	373 (12.9)	514 (12.2)	987 (35.0)	1245 (31.9)	185 (125, 320)	181 (118, 327)	NR	NR
McGinley et al, 2020	63.7±NR	63.7±NR	304 (69.6)	390 (69.3)	132 (30.2)	168 (29.8)	38 (8.7)	53 (9.4)	173 (39.6)	232 (41.2)	NR	NR	NR	NR
Verheugt et al, 1998	NR	NR	91 (84.0)	91 (84.0)	NR	NR	NR	NR	NR	NR	132 (18, 360)	132 (48, 360)	NR	NR
Żurowska-Wolak et al, 2021	64.4	±11.8	NR	NR	384 (69.6)		144 (26.1)		NR	NR	87 ±29		NR	NR

Identification of studies via databases and registers



	Experimental		Cont	rol		Odds
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Ran
1.1.1 In-hospital mortality						
Chung et al 2007	4	56	6	64	2.2%	0.74
d'Entremont 2020	17	482	7	227	4.1%	1.15
Giralt et al 2015	26	758	39	568	7.7%	0.48
Zurowska-Wolak et al 2021	13	251	25	284	5.6%	0.57
Subtotal (95% CI) medRxiv preprint doi: https://doi.org/10.1101/2024.01.22.24301634; this ver	sion posted January 25, 20	1547 D24. The copyright holder	for this	1143	19.6%	0.60
Total events It is made available under a CC-BY-NC-ND	no has granted medRxiv a 4.0 International license .	license to display the pre	print in 77			
Heterogeneity: $Tau^2 = 0.00$; C	$2hi^2 = 2.8$	87, df = 1	3 (P = 0.4)	41); $I^2 =$	0%	
Test for overall effect: $Z = 2.8$	B2 (P = 0.)	.005)				
1.1.2 30-day Mortality						
Bloom et al 2021	41	1373	48	1373	8.8%	0.85
Emilsson et al 2022	313	7628	395	7628	12.5%	0.78
Giralt et al 2020	125	2720	79	800	10.7%	0.44
Karlsson et al 2019	76	2898	131	4236	10.8%	0.84
McGinley et al 2020	11	437	47	563	5.9%	0.28
Subtotal (95% CI)		15056		14600	48.7%	0.63
Total events	566		700			
Heterogeneity: $Tau^2 = 0.10$; C	$chi^2 = 21$.18, df =	4 (P = 0)	.0003);	$ ^2 = 81\%$	
Test for overall effect: $Z = 2.8$	86 (P = 0.00)	.004)				
1.1.3 1-year mortality						
Cantor et al 2017	247	6165	155	3419	11.9%	0.88
Giralt et al 2015	31	758	49	568	8.3%	0.45
Giralt et al 2020	196	2720	122	800	11.4%	0.43
Subtotal (95% CI)		9643		4787	31.6%	0.56
Total events	474		326			
Heterogeneity: $Tau^2 = 0.19$; C	$2hi^2 = 21$.56, df =	2 (P < C	0.0001);	$ ^2 = 91\%$	
Test for overall effect: $Z = 2.1$	12 (P = 0)	.03)				
Total (95% CI)		26246		20530	100.0%	0.61

Total (95% Cl)2624620530100.0%0Total events11001103Heterogeneity: Tau² = 0.09; Chi² = 47.58, df = 11 (P < 0.00001); l² = 77%Test for overall effect: Z = 4.45 (P < 0.00001)</td>Test for subgroup differences: Chi² = 0.13, df = 2 (P = 0.94), l² = 0%



	Experim	ental	Cont	rol		Ode
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Ra
Bloom et al 2021	19	1373	26	1373	6.4%	0.
Braga et al 1998	2	23	1	25	0.4%	2.2
Cantor et al 2017	95	6165	77	3419	22.9%	0.
Chung et al 2007	1	56	2	64	0.4%	0.
Emilsson et al 2022	199	7628	199	7628	46.6%	1.
Giralt et al 2015	9	758	5	568	1.9%	1.
Giralt et al 2020	12	2720	6	800	2.4%	0.
Karlsson et al 2019	47	2897	92	4243	17.3%	0.
McGinley et al 2020	6	437	5	563	1.6%	1.
Total (95% CI)		22057		18683	100.0%	0.8
Total events	390		413			
Heterogeneity: Tau ² =	0.00; Ch	$i^2 = 8.3$	7, df = 8	(P = 0.4)	0); $I^2 = 4$	%
Test for overall effect:	Z = 2.03	(P = 0.0)	04)			



	Experin	Experimental		Control		Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI		
Bloom et al 2021	62	1373	65	1373	12.5%	0.95 [0.67, 1.36]		
Cantor et al 2017	58	6381	47	3681	11.0%	0.71 [0.48, 1.04]		
Chung et al 2007	9	56	10	64	2.1%	1.03 [0.39, 2.76]		
Emilsson et al 2022	405	16026	901	25605	37.3%	0.71 [0.63, 0.80]		
Giralt et al 2015	30	758	43	568	7.8%	0.50 [0.31, 0.81]		
Giralt et al 2020	160	2729	80	800	17.4%	0.56 [0.42, 0.74]		
Karlsson et al 2019	19	2898	40	4246	6.2%	0.69 [0.40, 1.20]		
McGinley et al 2020	17	437	45	563	5.7%	0.47 [0.26, 0.83]		1
Total (95% CI)		30658		36900	100.0%	0.68 [0.58, 0.78]		
Total events	760		1231					
Heterogeneity: Tau ² = 0.01; Chi ² = 9.62, df = 7 (P = 0.21); I ² = 27%								
Test for overall effect: Z = 5.27 (P < 0.00001)								Favours

Odds Ratio M-H, Random, 95% CI -----0.5 10

pretreatment Favours no pretreatment

preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a li perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .	e. Experimental Control				Odds Ratio		(
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI			M-H, I
Ariza et al 2013	153	566	69	414	7.7%	1.85 [1.35, 2.55]			
Bloom et al 2021	178	528	128	528	8.9%	1.59 [1.21, 2.08]			
Braga et al 1998	13	25	3	23	0.8%	7.22 [1.70, 30.64]			
Cantor et al 2017	1805	6381	712	3683	13.3%	1.65 [1.49, 1.82]			
Chung et al 2007	27	56	14	64	2.3%	3.33 [1.51, 7.34]			
d'Entremont 2020	215	482	42	227	6.5%	3.55 [2.43, 5.19]			
Emilsson et al 2022	4233	11188	3263	11188	14.0%	1.48 [1.40, 1.56]			
Fakhr-Mousavi et al 2021	9	92	6	77	1.3%	1.28 [0.44, 3.78]			
Giralt et al 2015	229	758	120	568	9.3%	1.62 [1.25, 2.08]			
Giralt et al 2020	734	2720	189	800	11.2%	1.19 [0.99, 1.44]			
Karlsson et al 2019	777	2898	811	4246	13.0%	1.55 [1.39, 1.74]			
McGinley et al 2020	111	437	136	563	8.4%	1.07 [0.80, 1.43]			
Verheught et al 1998	55	108	19	108	3.4%	4.86 [2.61, 9.06]			
Total (95% CI)		26239		22489	100.0%	1.68 [1.47, 1.91]			
Total events	8539		5512						
Heterogeneity: $Tau^2 = 0.03$;	$; Chi^2 = 5$	8.42, df	= 12 (P	< 0.000	01); $I^2 = 7$	9%			
Test for overall effect: Z = 7.79 (P < 0.00001)									U.J Irs protroati

Odds Ratio Random, 95% CI

